Takayuki Niitsu
Overview
Explore the profile of Takayuki Niitsu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hara R, Takeda Y, Enomoto T, Yoshimura H, Yamamoto M, Tanizaki S, et al.
J Allergy Clin Immunol Glob
. 2025 Mar;
4(2):100432.
PMID: 40046156
Background: Bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) are often misdiagnosed or undiagnosed, highlighting the need for more noninvasive and accessible diagnostic tools. Although exhaled breath condensate (EBC)...
2.
Hashimoto K, Abe Y, Fukushima K, Matsumoto Y, Saito H, Akamine Y, et al.
Emerg Infect Dis
. 2025 Mar;
31(3):624-627.
PMID: 40023820
We identified 2 novel species, Mycobacterium novusgordonae and M. shingordonae, from sputum specimens of pulmonary disease patients in Japan. Genetic and biochemical analyses revealed a close relationship with M. paragordonae....
3.
Yamamoto S, Horita N, Imai R, Niitsu T
Lung
. 2025 Jan;
203(1):22.
PMID: 39762564
Background: Along with lung volume reduction surgery (LVRS), bronchoscopic lung volume reduction is a treatment option for end-stage emphysema. However, comparisons among interventions remain insufficient. Methods: We searched on PubMed,...
4.
Hashimoto K, Abe Y, Fukushima K, Niitsu T, Komukai S, Miyamoto S, et al.
BMC Pulm Med
. 2024 Oct;
24(1):531.
PMID: 39448945
Background: The characteristics of bronchiectasis (BE) in Asia, including Japan, remain largely unknown. We aimed to provide insights into the clinical characteristics and treatment outcomes of BE, especially regarding nontuberculous...
5.
Fukushima K, Matsumoto Y, Abe Y, Hashimoto K, Motooka D, Kitada S, et al.
Antimicrob Agents Chemother
. 2024 Oct;
68(11):e0121324.
PMID: 39377582
This single-center retrospective study aimed to analyze the variability of macrolide resistance (MR) in 68 patients with complex pulmonary disease. Among 25 patients treated without macrolides, 13 (52%) reverted to...
6.
Nabeshima H, Niitsu T, Fukushima K, Kida H
Cell Mol Immunol
. 2023 May;
20(10):1095-1097.
PMID: 37147375
No abstract available.
7.
Fukushima K, Matsumoto Y, Matsuki T, Saito H, Motooka D, Komukai S, et al.
J Clin Microbiol
. 2023 Mar;
61(4):e0162622.
PMID: 36946719
Because nontuberculous mycobacterial pulmonary disease is a considerable health burden, a simple and clinically applicable analytical protocol enabling the identification of subspecies and drug-resistant disease is required to determine the...
8.
Niitsu T, Fukushima K, Komukai S, Takata S, Abe Y, Nii T, et al.
RMD Open
. 2023 Jan;
9(1).
PMID: 36690385
Objective: No studies have demonstrated the real-world efficacy of antifibrotics for progressive fibrosing interstitial lung disease (PF-ILD). Therefore, we evaluated the efficacy of antifibrotics in patients with PF-ILD. Methods: We...
9.
Kawasaki T, Takeda Y, Edahiro R, Shirai Y, Nogami-Itoh M, Matsuki T, et al.
Inflamm Regen
. 2022 Dec;
42(1):53.
PMID: 36451245
Background: The coronavirus disease 2019 (COVID-19) pandemic is widespread; however, accurate predictors of refractory cases have not yet been established. Circulating extracellular vesicles, involved in many pathological processes, are ideal...
10.
Wang Q, Edahiro R, Namkoong H, Hasegawa T, Shirai Y, Sonehara K, et al.
Nat Commun
. 2022 Aug;
13(1):4830.
PMID: 35995775
Coronavirus disease 2019 (COVID-19) is a recently-emerged infectious disease that has caused millions of deaths, where comprehensive understanding of disease mechanisms is still unestablished. In particular, studies of gene expression...